Masterman and colleagues have conducted a two-stage study in order to analyze the role of CTLA-4 promoter–exon 1 haplotypes in the age at onset, disease severity, and disease course in MS [128]. This evidence concerns the gene CTLA4 and myeloid sarcoma.